Abrexa Pharmaceuticals
San Diego, US · Delaware corporation
Founders & leadership
JE
J. Ernest VillafrancaExecutive
DH
David HugleyNamed on SEC filing
Board
DH
David HughleyBoard director
JJ
James J. TruchardBoard director
Reported raises · per SEC filings
Form D private placements$39.6M disclosed across 2 rounds · 2018–2025
▶$23MraisedApr 2025 · 2 investors · Other Health CareRule 506(b)
▶$23MraisedApr 2025 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David HughleyDirector
- James J. TruchardDirector
- J. Ernest VillafrancaExecutive Officer, Director
- Offering amount
- $23M
- Amount sold
- $23M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.6MraisedFeb 2019 · 7 investors · Other Health CareRule 506(b)
▶$16.6MraisedFeb 2019 · 7 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- James J. TruchardDirector
- David HugleyDirector
- J. Ernest VillafrancaExecutive Officer, Director
- Offering amount
- $16.6M
- Amount sold
- $16.6M
- Proceeds to insiders
- $180K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has Abrexa Pharmaceuticals raised?
- Abrexa Pharmaceuticals has disclosed $39.6M raised across 2 rounds.
- Where is Abrexa Pharmaceuticals headquartered?
- Abrexa Pharmaceuticals is headquartered in San Diego, US.